The results of preclinical studies indicate that the demise of immunogenic cells induced by cytotoxic agents could enable the cross-presentation of antigens, dendritic cell activation, and the induction of tumor-specific cytotoxic T cells labeled by CD8, a major component of the tumor-related immune system [23, 24]. This evidence concerns the gene CD8A and neoplasm.